Cargando…
Wegovy (semaglutide): a new weight loss drug for chronic weight management
Obesity is a growing epidemic within the USA. Because weight gain is associated with an increased risk of developing life-threatening comorbidities, such as hypertension or type 2 diabetes, there is great interest in developing non-invasive pharmacotherapeutics to help combat obesity. Glucagon-like...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717485/ https://www.ncbi.nlm.nih.gov/pubmed/34706925 http://dx.doi.org/10.1136/jim-2021-001952 |
_version_ | 1784624542119886848 |
---|---|
author | Singh, Gurdeep Krauthamer, Matthew Bjalme-Evans, Meghan |
author_facet | Singh, Gurdeep Krauthamer, Matthew Bjalme-Evans, Meghan |
author_sort | Singh, Gurdeep |
collection | PubMed |
description | Obesity is a growing epidemic within the USA. Because weight gain is associated with an increased risk of developing life-threatening comorbidities, such as hypertension or type 2 diabetes, there is great interest in developing non-invasive pharmacotherapeutics to help combat obesity. Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of antidiabetic medications that have shown promise in encouraging glycemic control and promoting weight loss in patients with or without type 2 diabetes. This literature review summarizes and discusses the weight loss results from the SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes), PIONEER (Peptide Innovation for Early Diabetes Treatment), and STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial programs. The SUSTAIN and PIONEER clinical trials studied the use of 1.0 mg, once-weekly, subcutaneous and oral semaglutide (a new GLP-1 homolog), respectively, on participants with type 2 diabetes. The STEP trial examined the effects of 2.4 mg, once-weekly, subcutaneous semaglutide on patients with obesity. Trial data and other pertinent articles were obtained via database search through the US National Library of Medicine Clinical Trials and the National Center for Biotechnology Information. All three clinical trials demonstrated that semaglutide (injected or oral) has superior efficacy compared with placebo and other antidiabetic medications in weight reduction, which led to Food and Drug Administration approval of Wegovy (semaglutide) for weight loss. |
format | Online Article Text |
id | pubmed-8717485 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-87174852022-01-12 Wegovy (semaglutide): a new weight loss drug for chronic weight management Singh, Gurdeep Krauthamer, Matthew Bjalme-Evans, Meghan J Investig Med Review Obesity is a growing epidemic within the USA. Because weight gain is associated with an increased risk of developing life-threatening comorbidities, such as hypertension or type 2 diabetes, there is great interest in developing non-invasive pharmacotherapeutics to help combat obesity. Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of antidiabetic medications that have shown promise in encouraging glycemic control and promoting weight loss in patients with or without type 2 diabetes. This literature review summarizes and discusses the weight loss results from the SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes), PIONEER (Peptide Innovation for Early Diabetes Treatment), and STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial programs. The SUSTAIN and PIONEER clinical trials studied the use of 1.0 mg, once-weekly, subcutaneous and oral semaglutide (a new GLP-1 homolog), respectively, on participants with type 2 diabetes. The STEP trial examined the effects of 2.4 mg, once-weekly, subcutaneous semaglutide on patients with obesity. Trial data and other pertinent articles were obtained via database search through the US National Library of Medicine Clinical Trials and the National Center for Biotechnology Information. All three clinical trials demonstrated that semaglutide (injected or oral) has superior efficacy compared with placebo and other antidiabetic medications in weight reduction, which led to Food and Drug Administration approval of Wegovy (semaglutide) for weight loss. BMJ Publishing Group 2022-01 2021-10-27 /pmc/articles/PMC8717485/ /pubmed/34706925 http://dx.doi.org/10.1136/jim-2021-001952 Text en © American Federation for Medical Research 2022. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Singh, Gurdeep Krauthamer, Matthew Bjalme-Evans, Meghan Wegovy (semaglutide): a new weight loss drug for chronic weight management |
title | Wegovy (semaglutide): a new weight loss drug for chronic weight management |
title_full | Wegovy (semaglutide): a new weight loss drug for chronic weight management |
title_fullStr | Wegovy (semaglutide): a new weight loss drug for chronic weight management |
title_full_unstemmed | Wegovy (semaglutide): a new weight loss drug for chronic weight management |
title_short | Wegovy (semaglutide): a new weight loss drug for chronic weight management |
title_sort | wegovy (semaglutide): a new weight loss drug for chronic weight management |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717485/ https://www.ncbi.nlm.nih.gov/pubmed/34706925 http://dx.doi.org/10.1136/jim-2021-001952 |
work_keys_str_mv | AT singhgurdeep wegovysemaglutideanewweightlossdrugforchronicweightmanagement AT krauthamermatthew wegovysemaglutideanewweightlossdrugforchronicweightmanagement AT bjalmeevansmeghan wegovysemaglutideanewweightlossdrugforchronicweightmanagement |